Bristol Myers Squibb vs Align Technology
Side-by-side comparison of AI visibility scores, market position, and capabilities
Princeton NJ biopharma (NYSE: BMY) at $48.3B 2024 revenue; Eliquis $13.3B, Opdivo $9.2B, Cobenfy schizophrenia launch; $23B acquisitions (Karuna+Mirati+RayzeBio) building next pipeline vs. Pfizer and Merck.
About
Bristol Myers Squibb (BMS) is a Princeton, New Jersey-based global biopharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: BMY) as an S&P 500 Healthcare component — discovering, developing, and delivering innovative medicines for serious diseases including cancer, cardiovascular disease, immunology, and neuroscience through approximately 34,000 employees worldwide. In fiscal year 2024, BMS reported total revenue of $48.3 billion (+7% year-over-year), with its Growth Portfolio generating $22.6 billion (+17%), driven by blockbusters Eliquis ($13.3B anticoagulant), Opdivo ($9.2B immuno-oncology), and Revlimid ($5.8B multiple myeloma). New product revenue surged 77% to $3.6 billion, led by schizophrenia treatment Cobenfy (formerly KarXT), CAR-T therapy Breyanzi, anemia drug Reblozyl, and Opdualag checkpoint inhibitor combination. CEO Dr. Christopher Boerner assumed leadership in November 2023, accelerating BMS's pipeline expansion through three transformative acquisitions in 2024: Karuna Therapeutics ($14B, Cobenfy/KarXT for schizophrenia and Alzheimer's agitation), Mirati Therapeutics ($4.8B, KRAS-targeted oncology), and RayzeBio ($4.1B, radiopharmaceutical cancer therapy).
San Jose clear aligner orthodontics inventor (NASDAQ: ALGN) at $3.23B 2024 revenue; 20 million Invisalign patient milestone Q1 2025 across 280,000+ doctors with iTero Lumina scanner competing with 3M Clarity for orthodontic clear aligner prescriptions.
About
Align Technology, Inc. is a San Jose, California-based global medical device company — publicly traded on NASDAQ (NASDAQ: ALGN) as an S&P 500 component — operating as the inventor of the Invisalign System and the world leader in clear aligner orthodontics, reaching 20 million Invisalign patients treated worldwide in Q1 2025 through a network of 280,000+ Invisalign-trained doctors across 100+ countries. In fiscal year 2024, Align reported $3.23 billion in total revenue with Q4 2024 revenue of $995.2 million (+4.0% year-over-year). Align's product portfolio comprises the Invisalign System of clear aligners, iTero intraoral digital scanners (including the iTero Lumina with 3X wider field of capture in a 50% smaller wand), and exocad CAD/CAM software for digital dental workflows. Manufacturing is based in Mexico with treatment planning performed in Costa Rica. CEO Joseph Hogan joined from GE Healthcare in 2015. Founded 1997 by Zia Chishti and Kelsey Wirth in San Jose.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.